TELA Bio Inc., a company specializing in soft-tissue reconstruction solutions, reported its financial results for the first quarter of 2025. The company achieved revenue of $18.5 million, marking a 12% increase compared to the same period last year and a 5% rise from the fourth quarter of 2024. This growth was driven by increased demand for their OviTex® and OviTex PRS Reinforced Tissue Matrix products, which saw revenue increases of approximately 15% and 2%, respectively, year-over-year. However, TELA Bio reported a net loss of $11.3 million for the first quarter of 2025, a significant increase from the $5.7 million net loss recorded in the same quarter of 2024. Cash and cash equivalents as of March 31, 2025, totaled $42.8 million. The company reiterated its full-year 2025 revenue guidance, projecting a range of $85.0 million to $88.0 million, which would represent a 23% to 27% growth over the full year 2024. Operating expenses for 2025 are expected to remain flat compared to 2024. A notable development in the company's operations is the full U.S. commercial launch of larger-sized OviTex PRS, aimed at simplifying complex plastic and reconstructive procedures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.